<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02627027</url>
  </required_header>
  <id_info>
    <org_study_id>158BE15004</org_study_id>
    <nct_id>NCT02627027</nct_id>
  </id_info>
  <brief_title>A Clinical Study to Compare the Pharmacokinetic Characteristics of CKD-395 0.25/750 mg in Healthy Male Volunteers</brief_title>
  <official_title>A Randomized, Open-label, Single Dose, 2-way Crossover Study to Compare the Pharmacokinetic Characteristics of CKD-395 0.25/750 mg in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a randomized, open-label, single dose, 2-way crossover study to compare the&#xD;
      pharmacokinetic characteristics of CKD-395 0.25/750 mg in healthy male volunteers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To healthy male subjects of twenty six(26), following treatments are administered dosing in&#xD;
      each period fed condition(high fat meals) and wash-out period is a minimum of 7 days.&#xD;
&#xD;
      Treatment A(Reference Drug): DuvieTM Tab. 0.5mg 1T + Glucodaun OR Tab. 750mg 2T Treatment&#xD;
      B(Test Drug): CKD-395 0.25/750mg Tab. 2T Pharmacokinetic blood samples are collected up to&#xD;
      48hrs. Safety and pharmacokinetic are assessed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUClast of Lobeglitazone</measure>
    <time_frame>Lobeglitazone: 0(Pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 and 48hrs</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast of metformin</measure>
    <time_frame>Metformin: 0(Pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24 and 48hrs</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of Lobeglitazone</measure>
    <time_frame>Lobeglitazone: 0(Pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 and 48hrs</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of Lobeglitazone Metformin</measure>
    <time_frame>Metformin: 0(Pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24 and 48hrs</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUCinf of Lobeglitazone</measure>
    <time_frame>Lobeglitazone: 0(Pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 and 48hrs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf of Metformin</measure>
    <time_frame>Metformin: 0(Pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24 and 48hrs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of Lobeglitazone</measure>
    <time_frame>Lobeglitazone: 0(Pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 and 48hrs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of Metformin</measure>
    <time_frame>Metformin: 0(Pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24 and 48hrs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of Lobeglitazone</measure>
    <time_frame>Lobeglitazone: 0(Pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 and 48hrs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of Metformin</measure>
    <time_frame>Metformin: 0(Pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24 and 48hrs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F of Lobeglitazone</measure>
    <time_frame>Lobeglitazone: 0(Pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 and 48hrs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F of Metformin</measure>
    <time_frame>Metformin: 0(Pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24 and 48hrs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd/F of Lobeglitazone</measure>
    <time_frame>Lobeglitazone: 0(Pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 and 48hrs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd/F of Metformin</measure>
    <time_frame>Metformin: 0(Pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24 and 48hrs</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Diabetes Mellitus, Type II</condition>
  <arm_group>
    <arm_group_label>RT group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>R: Reference drug(Duvie Tab. 0.5mg 1T, Glucodaun OR Tab. 750mg 2T) T: Test drug(CKD-395 0.25/750 mg 2T)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TR group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>T: Test drug(CKD-395 0.25/750 mg 2T) R: Reference drug(Duvie Tab. 0.5mg 1T, Glucodaun OR Tab. 750mg 2T)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duvie Tab. 0.5mg, Glucodaun OR Tab. 750mg</intervention_name>
    <description>oral administration</description>
    <arm_group_label>RT group</arm_group_label>
    <arm_group_label>TR group</arm_group_label>
    <other_name>Lobeglitazone Sulfate 0.5mg, Metformin HCl 1500mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-395 0.25/750mg</intervention_name>
    <description>oral administration</description>
    <arm_group_label>RT group</arm_group_label>
    <arm_group_label>TR group</arm_group_label>
    <other_name>Lobeglitazone Sulfate 0.25mg, Metformin HCl 750mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy man older than 19 years at the time of screening.&#xD;
&#xD;
          2. BMI more than 17.5kg/m2 and less than 30.5kg/m2 and weight more than 55kg&#xD;
&#xD;
          3. Subject without congenital or chronic diseases and no psychotic symptoms or findings&#xD;
             from the medical examination.&#xD;
&#xD;
          4. Suitable subject who is determined by laboratory tests such as hematology tests,blood&#xD;
             chemistry, urinalysis test according to the characteristics of the drug and screening&#xD;
             tests such as ECG test.&#xD;
&#xD;
          5. Subject who fully understand the clinical trials after in-depth explanation given&#xD;
             prior to the clinical study, decided to join the clinical trials by their will and&#xD;
             signed consent form which approved by Chonbuk National University Hospital IRB.&#xD;
&#xD;
          6. Subjects who are able to comply with all scheduled visits, laboratory tests and other&#xD;
             procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects who has a history of blood, kidneys, endocrine, respiratory,&#xD;
             gastrointestinal, urinary, cardiovascular, hepatic, psychiatric, neurological or&#xD;
             allergic diseases that is clinically significant (Except untreated asymptomatic&#xD;
             seasonal allergies at the time of administration)&#xD;
&#xD;
          2. Subjects who has a history of gastrointestinal disease or gastrointestinal surgery&#xD;
             which can affect drug absorption.&#xD;
&#xD;
          3. Subjects who show AST or AST &gt; 2 times upper limit of normal range.&#xD;
&#xD;
          4. Subjects who drink Alcohol &gt; 210g/week within 6 months prior to the screening.&#xD;
&#xD;
          5. Subjects who take the medication involved in other clinical trials or bioequivalence&#xD;
             tests within three months before the first dose medication characters.&#xD;
&#xD;
          6. Subjects who show Systolic Blood Pressure ≥ 140 mmHg or Diastolic Blood Pressure ≥ 90&#xD;
             mmHg at screening.&#xD;
&#xD;
          7. Subjects who have history of alcohol or drug abuse, within 1 year&#xD;
&#xD;
          8. Subjects who treated with metabolizing enzyme inducers or inhibitors such as barbitals&#xD;
             within 30days prior to the first dosing.&#xD;
&#xD;
          9. Smoker ( ≥ 20cigarettes/day)&#xD;
&#xD;
         10. Subjects who takes ETC or OTC medicine within 10days before the first IP&#xD;
             administration.&#xD;
&#xD;
         11. Subjects who do the whole blood donation within two months or component blood donation&#xD;
             within 1month prior to the first dosing.&#xD;
&#xD;
         12. Subjects who can increase risk due to clinical test and administration of drugs or has&#xD;
             Severe grade / chronic medical, mental condition or abnormal laboratory result that&#xD;
             may interfere with the analysis of test results.&#xD;
&#xD;
         13. Patients with hypersensitivity to lobeglitazone or any other thiazolidinediones (&#xD;
             Rosiglitazone, Rioglitazone) and to Metformin or any other biguanides&#xD;
&#xD;
         14. Patients with severe heart failure or congestive heart failure of needing drug therapy&#xD;
&#xD;
         15. Patients with liver disease&#xD;
&#xD;
         16. Patients with severe renal disease&#xD;
&#xD;
         17. Patients with diabetes mellitus with ketoacidosis, diabetes coma and prior&#xD;
&#xD;
         18. Patients before or after surgery, with severe infections, severe trauma&#xD;
&#xD;
         19. Subjects with hereditary diseases of galactose intolerance, Lapp lactase deficiency or&#xD;
             glucose-galactose malabsorption&#xD;
&#xD;
         20. Patients with renal disease or renal failure caused by cardiovascular collapse, acute&#xD;
             myocardial infarction, sepsis (Serum creatinine ≥ 1.5mg/dL or abnormal creatine&#xD;
             clearance)&#xD;
&#xD;
         21. Patients who had a test to injecting radioactive iodine in vein&#xD;
&#xD;
         22. Patients with severe infections or severe traumatic whole body injuries&#xD;
&#xD;
         23. Patients with undernourishment condition or starvation state or hyposthenia or&#xD;
             hypopituitarism, or hypoadrenalism&#xD;
&#xD;
         24. Patients with respiratory failure, or stomach disease&#xD;
&#xD;
         25. Subjects who is not able to intake high fat meals&#xD;
&#xD;
         26. Subjects who is not able to comply with guidelines described in the protocol.&#xD;
&#xD;
         27. Subjects who is determined by investigator's decision as unsuitable for clinical trial&#xD;
             participation.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Chonbuk National University Hospital</name>
      <address>
        <city>Jeonju-si</city>
        <state>Jeollabuk-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <study_first_submitted>December 8, 2015</study_first_submitted>
  <study_first_submitted_qc>December 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2015</study_first_posted>
  <last_update_submitted>January 5, 2016</last_update_submitted>
  <last_update_submitted_qc>January 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

